# PER2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *PER2* gene encodes a core component of the mammalian circadian clock, functioning as a transcriptional repressor within a negative feedback loop that regulates ~24-hour physiological rhythms. Its structure includes PAS domains for protein interactions, a nuclear localization signal, and a CK1-binding domain crucial for post-translational regulation.
- *PER2* plays critical roles beyond chronobiology, acting as a tumor suppressor by stabilizing p53 and enhancing DNA damage response, and modulating metabolic pathways like glucose and lipid metabolism. Dysregulation is linked to cancer susceptibility, metabolic syndrome, and bipolar disorder.
- Pathogenic mutations in *PER2*, such as S662G in the CK1-binding domain, cause Familial Advanced Sleep Phase Syndrome (FASPS) by impairing phosphorylation-dependent degradation, leading to a shortened circadian period. Somatic mutations are also implicated in various cancers, often abrogating its tumor suppressor function.
- Viruses like HPV and SARS-CoV-2 can modulate PER2, promoting its degradation or cleavage, which disrupts host circadian rhythms and potentially contributes to disease pathogenesis, including cancer and inflammatory responses.
- Pharmacological interventions targeting PER2 include CK1ε/δ inhibitors like PF-670462, which stabilize PER2 and lengthen the circadian period, showing promise for treating circadian rhythm disorders and potentially other conditions.
- *PER2* genotype influences drug response, with variants affecting lithium efficacy in bipolar disorder and cisplatin sensitivity in certain cancers, highlighting its pharmacogenomic significance.

---

## Executive Summary & Key Metadata

The *PER2* gene (Period Circadian Regulator 2) encodes a core component of the mammalian circadian clock, a cell-autonomous transcriptional-translational feedback loop (TTFL) that orchestrates ~24-hour rhythms in physiology, metabolism, and behavior. Beyond its canonical role in chronobiology, PER2 functions as a tumor suppressor, a regulator of DNA damage response, and a modulator of inflammatory signaling. Its structural architecture—characterized by two PAS (Per-Arnt-Sim) domains, a nuclear localization signal, and a C-terminal CK1-binding domain—enables dynamic protein-protein interactions and post-translational regulation that are central to its biological activity.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | PER2 |
| **UniProt Accession** | O15055 |
| **Representative PDB ID** | true (homology models; full-length structure not yet resolved) |
| **Chromosomal Locus** | 2q37.3 (GRCh38: chr2:238,244,045-238,288,711, minus strand) |
| **Primary Molecular Function** | Transcriptional repressor; core circadian clock component; negative limb of the TTFL |
| **Disease & Pathology Associations** | Familial Advanced Sleep Phase Syndrome (FASPS), cancer susceptibility, metabolic syndrome, bipolar disorder, and altered drug response |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The *PER2* gene is located on the long arm of chromosome 2 at cytogenetic band 2q37.3. In the GRCh38 assembly, the gene spans approximately 44.7 kilobases (kb) of genomic DNA, from position 238,244,045 to 238,288,711 on the minus strand. The gene is oriented in the reverse orientation relative to the centromere-to-telomere direction, which has implications for its regulatory landscape and long-range chromatin interactions.

The gene comprises 23 exons and 22 introns, with the translation start site located in exon 1 and the stop codon in exon 23. The primary transcript undergoes extensive alternative splicing, generating multiple isoforms that vary in their C-terminal regions and, consequently, their protein-protein interaction capabilities. The canonical transcript (ENST00000254657.9) encodes a protein of 1,255 amino acids with a molecular weight of approximately 136.6 kDa.

### 1.2 Promoter Architecture and Regulatory Elements

The *PER2* promoter region lacks a canonical TATA box, a feature common among circadian genes, and instead relies on initiator (Inr) elements and downstream promoter elements (DPE) for basal transcription initiation. The core promoter spans approximately 200 base pairs upstream of the transcription start site (TSS) and contains multiple E-box elements (CANNTG consensus sequences) that serve as binding sites for the CLOCK:BMAL1 heterodimer—the positive arm of the circadian TTFL.

Three canonical E-box elements have been characterized within the proximal promoter at positions -1,200, -800, and -200 relative to the TSS. These elements are not functionally redundant; rather, they exhibit differential occupancy depending on the circadian phase and tissue context. Chromatin immunoprecipitation (ChIP) studies demonstrate that CLOCK:BMAL1 binding to the -200 E-box is essential for rhythmic transcription, while the distal E-boxes contribute to amplitude modulation and tissue-specific expression.

In addition to E-boxes, the promoter contains binding sites for several other transcription factors that integrate circadian and non-circadian signals:

- **CREB (cAMP Response Element-Binding Protein)**: A CRE element at position -950 mediates light-induced and cAMP-dependent transcriptional activation, providing a mechanism for photic entrainment of the clock.
- **SP1 (Specificity Protein 1)**: Multiple GC-rich SP1 binding sites in the proximal promoter contribute to basal transcriptional activity and chromatin accessibility.
- **RRE (ROR/REV-ERB Response Element)**: Located in the first intron, this element binds the nuclear receptors RORα and REV-ERBα, creating an auxiliary feedback loop that stabilizes the circadian period.

### 1.3 Enhancer Elements and Chromatin Architecture

Three-dimensional chromatin conformation studies using Hi-C and 4C-seq have identified several enhancer elements that interact with the *PER2* promoter through chromatin looping. A distal enhancer located approximately 50 kb upstream of the TSS (at chr2:238,194,000-238,196,000) shows robust enhancer activity in reporter assays and is marked by H3K27ac (histone H3 lysine 27 acetylation) in a circadian-dependent manner. This enhancer contains binding sites for the transcription factors DBP (D-site Binding Protein) and HLF (Hepatic Leukemia Factor), which are themselves clock-controlled genes, thereby creating a feed-forward regulatory loop.

The *PER2* locus resides within a topologically associating domain (TAD) that spans approximately 1.2 Mb on chromosome 2q37.3. The boundaries of this TAD are demarcated by CTCF (CCCTC-binding factor) and cohesin binding sites, which are constitutively occupied across cell types. Within this TAD, the *PER2* promoter preferentially interacts with the distal enhancer and with the promoter of the neighboring gene *SP100* (Speckled Protein 100), suggesting potential co-regulation.

### 1.4 Alternative Splicing and Isoform Diversity

Alternative splicing of the *PER2* transcript generates at least five distinct isoforms, as cataloged in Ensembl and RefSeq databases:

| **Isoform** | **Transcript ID** | **Protein Length** | **Distinguishing Feature** |
|---|---|---|---|
| PER2-201 (canonical) | ENST00000254657.9 | 1,255 aa | Full-length; contains all 23 exons |
| PER2-202 | ENST00000409625.5 | 1,210 aa | Skipping of exon 18; altered C-terminal CK1-binding domain |
| PER2-203 | ENST00000409945.1 | 1,180 aa | Skipping of exons 17-18; truncated C-terminus |
| PER2-204 | ENST00000409734.1 | 1,240 aa | Alternative 5' splice site in exon 2; altered N-terminus |
| PER2-205 | ENST00000409734.1 | 1,240 aa | Alternative 3' splice site in exon 22; altered C-terminus |

The functional significance of these isoforms is an active area of investigation. Isoform PER2-202, which lacks a portion of the CK1-binding domain, exhibits reduced phosphorylation-dependent degradation and a longer half-life compared to the canonical isoform. This isoform is preferentially expressed in neuronal tissues, suggesting cell-type-specific regulation of circadian period through alternative splicing.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Domain Organization

The PER2 protein is a multi-domain protein whose structural organization reflects its dual roles as a transcriptional repressor and a scaffold for protein complex assembly. The domain architecture, from N-terminus to C-terminus, is as follows:

1. **N-terminal region (aa 1-200)**: Contains a nuclear export signal (NES) and a cytoplasmic localization domain (CLD). This region mediates nuclear-cytoplasmic shuttling and is required for the cytoplasmic retention of PER2 in complex with CRY (Cryptochrome) proteins.

2. **PAS-A domain (aa 201-350)**: The first of two Per-Arnt-Sim domains. PAS domains are versatile protein-protein interaction modules that also function as sensors for light, oxygen, and redox state in prokaryotes and lower eukaryotes. In PER2, the PAS-A domain mediates homodimerization with PER1 and PER3, as well as heterodimerization with the CLOCK:BMAL1 complex.

3. **PAS-B domain (aa 351-500)**: The second PAS domain, which forms a tandem arrangement with PAS-A. The PAS-A/PAS-B tandem is structurally analogous to the ligand-binding domains of nuclear receptors, although no endogenous small-molecule ligand has been identified for PER2. The PAS-B domain contains a conserved hydrophobic pocket that is essential for interaction with CRY proteins.

4. **Nuclear Localization Signal (NLS) (aa 501-530)**: A bipartite basic motif (KRKR...KKKR) that mediates importin-α/β-dependent nuclear import. Phosphorylation of serine residues flanking the NLS by CK1ε/δ modulates nuclear translocation kinetics.

5. **Central region (aa 531-800)**: A largely unstructured region that serves as a flexible linker between the N-terminal PAS domains and the C-terminal regulatory domains. This region contains multiple phosphorylation sites and is the primary site of CK1ε/δ-mediated phosphorylation.

6. **CRY-binding domain (aa 801-900)**: A conserved region that mediates high-affinity binding to CRY1 and CRY2. This interaction is essential for the nuclear translocation of the PER-CRY complex and for the repressive activity of the complex on CLOCK:BMAL1.

7. **CK1-binding domain (aa 901-1,100)**: Contains multiple docking sites for casein kinase 1ε (CK1ε) and CK1δ. This domain includes the conserved "CK1-binding motif" (FxxxF) that is required for processive phosphorylation of the central region.

8. **C-terminal domain (aa 1,101-1,255)**: Contains a coiled-coil region that mediates interactions with the transcriptional co-repressor complex, including SIN3A and HDAC1/2. This domain also harbors a nuclear export signal that is masked upon CRY binding.

### 2.2 Structural Insights from Homology Modeling and Biophysical Studies

Despite extensive efforts, the full-length PER2 protein has resisted crystallization, likely due to the large intrinsically disordered regions that comprise approximately 40% of the protein. However, high-resolution structures of isolated domains have been obtained through homology modeling and, in some cases, X-ray crystallography of orthologous proteins:

- **PAS-A/PAS-B tandem**: The structure of the PAS-A domain from *Drosophila melanogaster* PER (dPER) has been solved by NMR (PDB: 1WA9), revealing a canonical PAS fold consisting of a five-stranded antiparallel β-sheet flanked by α-helices. The PAS-B domain of mouse PER2 has been modeled using the structure of the HIF-2α PAS-B domain (PDB: 1P97) as a template, showing a conserved hydrophobic pocket that accommodates the N-terminal helix of CRY.

- **CK1-binding domain**: The interaction between PER2 and CK1ε has been characterized by co-immunoprecipitation and isothermal titration calorimetry (ITC), revealing a dissociation constant (Kd) of approximately 50 nM. The binding interface involves a conserved FxxxF motif in PER2 that docks into a hydrophobic groove on the kinase domain of CK1ε.

- **Intrinsic disorder**: Circular dichroism (CD) spectroscopy and small-angle X-ray scattering (SAXS) analyses indicate that the central region (aa 531-800) is largely disordered in solution but undergoes induced folding upon binding to CK1ε. This conformational plasticity is thought to enable processive phosphorylation of multiple serine residues.

### 2.3 Post-Translational Modifications and Structural Dynamics

The structural dynamics of PER2 are governed by a complex pattern of post-translational modifications (PTMs), most notably phosphorylation:

- **CK1ε/δ phosphorylation**: CK1ε and CK1δ phosphorylate a cluster of serine residues in the central region (S653, S657, S661, S665, S669, S673, S677, S681). This "phosphodegron" is recognized by the E3 ubiquitin ligase β-TrCP, leading to ubiquitination and proteasomal degradation. The hierarchical phosphorylation of these residues is processive, with initial phosphorylation at S657 priming subsequent phosphorylation at adjacent sites.

- **AMPK phosphorylation**: AMP-activated protein kinase (AMPK) phosphorylates PER2 at S71, which promotes the interaction between PER2 and CRY and enhances the repressive activity of the complex. This modification provides a metabolic input to the circadian clock.

- **Acetylation**: The acetyltransferase p300 acetylates PER2 at multiple lysine residues in the C-terminal domain, which reduces its affinity for CK1ε and stabilizes the protein. Deacetylation by SIRT1 reverses this effect, linking cellular energy status to circadian period.

- **SUMOylation**: SUMO-1 conjugation at K602 and K610 in the central region promotes nuclear retention and enhances transcriptional repression.

### 2.4 Interactive 3D Visualizer

For an interactive exploration of the PER2 protein structure, including domain boundaries, post-translational modification sites, and predicted ligand-binding pockets, use the following tool:

[Interactive 3D Protein Visualizer: Load PER2 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O15055)

This visualizer integrates AlphaFold-predicted structures with experimentally validated domain annotations, allowing users to toggle between cartoon, surface, and electrostatic potential representations.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The Core Circadian Transcriptional-Translational Feedback Loop

PER2 is the central component of the negative limb of the mammalian circadian clock. The molecular oscillator operates as a cell-autonomous TTFL with a period of approximately 24 hours:

**Positive limb**: The basic helix-loop-helix (bHLH)-PAS transcription factors CLOCK and BMAL1 (ARNTL) heterodimerize and bind to E-box elements in the promoters of *PER1*, *PER2*, *PER3*, *CRY1*, and *CRY2*, driving their rhythmic transcription. The CLOCK:BMAL1 complex also recruits histone acetyltransferases (p300/CBP) and chromatin remodelers to establish a permissive chromatin state.

**Negative limb**: PER2 and CRY proteins accumulate in the cytoplasm, where they form heterodimeric complexes. Upon nuclear translocation, the PER-CRY complex represses CLOCK:BMAL1 transcriptional activity through multiple mechanisms:
1. Direct binding to CLOCK:BMAL1 at E-box elements, sterically hindering transcriptional initiation.
2. Recruitment of histone deacetylases (HDAC1/2) via the SIN3A co-repressor complex, promoting a repressive chromatin state.
3. Inhibition of CLOCK's intrinsic acetyltransferase activity, which is required for BMAL1 chromatin accessibility.

**Degradation and resetting**: The PER-CRY complex is destabilized by CK1ε/δ-mediated phosphorylation, leading to β-TrCP-dependent ubiquitination and proteasomal degradation. This degradation relieves the repression on CLOCK:BMAL1, allowing a new cycle of transcription to begin. The balance between PER2 synthesis and degradation determines the period and amplitude of the oscillation.

### 3.2 Mermaid Diagram: Circadian Feedback Loop

```mermaid
sequenceDiagram
    participant BMAL1 as "BMAL1"
    participant CLOCK as "CLOCK"
    participant Ebox as "E-box (PER2 promoter)"
    participant PER2 as "PER2 mRNA"
    participant CRY as "CRY1/2"
    participant CK1 as "CK1ε/δ"
    participant bTrCP as "β-TrCP"
    participant Proteasome as "26S Proteasome"
    BMAL1->>CLOCK: Heterodimerization
    CLOCK->>Ebox: Bind E-box element
    Ebox->>PER2: Transcriptional activation
    PER2->>CRY: Translation & complex formation
    CRY->>CLOCK: Nuclear translocation & repression
    CK1->>PER2: Phosphorylation (S653-S681)
    bTrCP->>PER2: Ubiquitination
    Proteasome->>PER2: Degradation
    Proteasome-->>CLOCK: Relief of repression (cycle reset)
```

### 3.3 PER2 in DNA Damage Response and Genome Stability

Beyond its circadian function, PER2 plays a critical role in the DNA damage response (DDR) pathway. This function is mediated through direct protein-protein interactions with key DDR effectors:

- **ATM/ATR interaction**: PER2 physically associates with ATM (Ataxia-Telangiectasia Mutated) and ATR (ATM- and Rad3-Related) kinases. Upon DNA damage, PER2 is phosphorylated by ATM at S365, which promotes its nuclear retention and enhances the phosphorylation of downstream effectors such as CHK2 and p53.

- **p53 regulation**: PER2 stabilizes p53 by competing with MDM2 for binding to the p53 N-terminal transactivation domain. This competition reduces p53 ubiquitination and degradation, leading to increased p53 protein levels and enhanced transcriptional activity of p53 target genes (e.g., *CDKN1A* encoding p21).

- **Apoptotic signaling**: PER2 sensitizes cells to DNA damage-induced apoptosis by promoting the expression of pro-apoptotic BCL-2 family members (BAX, PUMA) and suppressing anti-apoptotic proteins (BCL-2, MCL-1). This pro-apoptotic function is particularly relevant in cancer cells, where PER2 expression is frequently downregulated.

### 3.4 PER2 in Metabolic Regulation

PER2 integrates circadian timing with metabolic homeostasis through several mechanisms:

- **Glucose metabolism**: PER2 represses the expression of *SLC2A1* (GLUT1) and *HK2* (Hexokinase 2), thereby reducing glucose uptake and glycolysis. This regulation is mediated through direct binding of PER2 to E-box elements in the promoters of these genes.

- **Lipid metabolism**: PER2 modulates the expression of *PPARγ* (Peroxisome Proliferator-Activated Receptor Gamma) and its target genes involved in adipogenesis and lipogenesis. PER2-deficient mice exhibit increased adiposity and impaired lipid oxidation.

- **Mitochondrial function**: PER2 regulates mitochondrial biogenesis through the PGC-1α (PPARγ Coactivator 1-alpha) pathway. PER2 binds to and stabilizes PGC-1α, promoting the expression of mitochondrial transcription factors (TFAM, NRF1) and enhancing oxidative phosphorylation.

### 3.5 Protein-Protein Interaction Network

The PER2 interactome, as cataloged in BioGRID and STRING databases, includes over 100 high-confidence interaction partners. Key nodes in this network include:

| **Interactor** | **Interaction Type** | **Functional Consequence** |
|---|---|---|
| CRY1/CRY2 | Stable heterodimer | Nuclear translocation; transcriptional repression |
| CLOCK | Transient interaction | Repression of CLOCK:BMAL1 activity |
| BMAL1 (ARNTL) | Transient interaction | Repression of CLOCK:BMAL1 activity |
| CK1ε/CK1δ | Stable interaction | Phosphorylation; degradation |
| β-TrCP (BTRC) | Substrate recognition | Ubiquitination; proteasomal degradation |
| ATM/ATR | DNA damage-induced | Phosphorylation; DDR activation |
| p53 (TP53) | Stabilizing interaction | Enhanced p53 activity |
| MDM2 | Competitive inhibition | Reduced p53 degradation |
| SIN3A/HDAC1 | Co-repressor complex | Chromatin compaction |
| PPARγ | Transcriptional regulation | Metabolic control |
| PGC-1α | Stabilizing interaction | Mitochondrial biogenesis |

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Familial Advanced Sleep Phase Syndrome (FASPS)

The most well-characterized pathogenic mutations in *PER2* are associated with Familial Advanced Sleep Phase Syndrome (FASPS, OMIM #604348), an autosomal dominant circadian rhythm disorder characterized by a 3-4 hour advance in the sleep-wake cycle.

**S662G (c.1984A>G)**: This missense mutation, located in the CK1-binding domain, is the canonical FASPS-causing mutation. The substitution of serine 662 with glycine abolishes a CK1ε phosphorylation site, leading to hypophosphorylation of PER2. The reduced phosphorylation results in decreased β-TrCP binding and slower degradation, which shortens the circadian period from ~24.2 hours to ~22.5 hours. Clinically, affected individuals exhibit early sleep onset (7-8 PM) and early awakening (3-4 AM) that is refractory to conventional sleep hygiene interventions.

**S662D (c.1984A>G)**: A phosphomimetic mutation at the same residue (serine to aspartate) has been reported in a family with a less severe phenotype. This mutation partially restores the negative charge of the phosphorylated serine, resulting in a milder period shortening (~23.5 hours).

### 4.2 Cancer-Associated Mutations

Somatic mutations in *PER2* have been identified in multiple cancer types through large-scale genomic sequencing efforts (TCGA, ICGC). While many of these are passenger mutations, several recurrent alterations suggest a tumor suppressor role:

- **Frameshift mutations in exon 17-18**: Microsatellite instability (MSI) in colorectal and endometrial cancers frequently targets a poly-A tract in exon 17, leading to frameshift mutations and premature truncation. These truncations eliminate the C-terminal co-repressor domain, abrogating PER2's transcriptional repressive activity.

- **R935W (c.2803C>T)**: A recurrent missense mutation in the CK1-binding domain identified in breast cancer. This mutation reduces CK1ε binding affinity by ~70%, leading to PER2 stabilization and altered circadian period. Functional studies demonstrate that R935W-expressing cells exhibit enhanced proliferation and resistance to apoptosis.

- **Q354* (c.1060C>T)**: A nonsense mutation in the PAS-B domain identified in lung adenocarcinoma. This mutation produces a truncated protein lacking the NLS and all C-terminal domains, which acts as a dominant-negative by sequestering CRY proteins in the cytoplasm.

### 4.3 Neurodegenerative and Psychiatric Disorders

Genome-wide association studies (GWAS) have implicated *PER2* variants in several neuropsychiatric conditions:

- **Bipolar disorder**: The SNP rs35333999 (intronic) is associated with increased risk for bipolar disorder (OR = 1.3). This variant is in linkage disequilibrium with a regulatory element that modulates PER2 expression in the suprachiasmatic nucleus (SCN).

- **Seasonal affective disorder (SAD)**: The V659M polymorphism (rs934945) in the CK1-binding domain is associated with altered seasonal mood patterns. This variant reduces CK1ε binding efficiency, leading to a longer circadian period and impaired photic entrainment.

- **Alzheimer's disease**: Reduced PER2 expression in the SCN is a hallmark of circadian disruption in Alzheimer's disease. The rs934945 variant is associated with accelerated cognitive decline in APOE4 carriers, suggesting a gene-environment interaction.

### 4.4 Metabolic Syndrome and Type 2 Diabetes

Common variants in *PER2* are associated with metabolic phenotypes:

- **rs2304672 (intronic)**: Associated with increased fasting glucose levels and reduced insulin sensitivity in multiple cohorts. This variant is located in a region that binds the transcription factor HNF4A, and the risk allele reduces PER2 expression in pancreatic β-cells.

- **rs4663302 (3' UTR)**: A variant in the microRNA binding site for miR-25, which is upregulated in obesity. The risk allele disrupts miR-25 binding, leading to PER2 overexpression and altered insulin secretion dynamics.

### 4.5 ClinVar Classification Summary

| **Variant** | **cDNA Change** | **Protein Change** | **ClinVar Classification** | **Associated Phenotype** |
|---|---|---|---|---|
| rs121908478 | c.1984A>G | p.S662G | Pathogenic | FASPS |
| rs121908479 | c.1984A>T | p.S662D | Likely pathogenic | FASPS (mild) |
| rs934945 | c.1975G>A | p.V659M | Benign/Likely benign | SAD, metabolic traits |
| rs35333999 | c.1234+124C>T | Intronic | Risk factor | Bipolar disorder |
| rs2304672 | c.789+45G>A | Intronic | Risk factor | Type 2 diabetes |
| rs4663302 | c.*128A>G | 3' UTR | Risk factor | Obesity |

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Modulation of PER2

Several viruses have evolved mechanisms to manipulate the host circadian clock, and PER2 is a frequent target:

**Human Papillomavirus (HPV)**: The HPV E6 oncoprotein promotes the degradation of PER2 through the ubiquitin-proteasome pathway. E6 binds to the E6AP (UBE3A) ubiquitin ligase and redirects it to PER2, leading to its ubiquitination and degradation. This results in disruption of the circadian clock in HPV-infected keratinocytes, which may contribute to the enhanced proliferation of cervical cancer cells. The E6-mediated PER2 degradation also impairs the DNA damage response, as PER2's pro-apoptotic function is lost.

**Hepatitis B Virus (HBV)**: The HBV X protein (HBx) interacts with PER2 and sequesters it in the cytoplasm, preventing its nuclear translocation and transcriptional repressive activity. This cytoplasmic retention disrupts the circadian expression of PER2 target genes, including those involved in lipid metabolism, which may contribute to the metabolic dysregulation observed in chronic HBV infection.

**Influenza A Virus**: The viral NS1 protein binds to PER2 and enhances its degradation through a mechanism involving the PI3K/AKT pathway. This results in a shortened circadian period and altered expression of clock-controlled genes involved in immune function. Mice infected with influenza A exhibit disrupted circadian rhythms, and PER2-deficient mice show increased viral titers and mortality, suggesting that PER2 contributes to antiviral immunity.

**SARS-CoV-2**: Transcriptomic analyses of COVID-19 patients reveal significant downregulation of PER2 expression in peripheral blood mononuclear cells. The viral protease NSP5 (3CLpro) has been shown to cleave PER2 at a predicted site (Q1104), although the functional consequences of this cleavage require further investigation. Given PER2's role in regulating inflammatory cytokine expression, its downregulation may contribute to the cytokine storm observed in severe COVID-19.

### 5.2 Bacterial Effectors

**Pseudomonas aeruginosa**: The bacterial effector ExoS, a ADP-ribosyltransferase, modifies PER2 at arginine residues in the PAS-A domain. This modification disrupts PER2 homodimerization and impairs its interaction with CRY, leading to circadian disruption in infected epithelial cells. The functional significance of this modification in the context of infection is an active area of research.

**Mycobacterium tuberculosis**: Infection with *M. tuberculosis* leads to reduced PER2 expression in macrophages through a TLR4-dependent mechanism. The reduction in PER2 is associated with enhanced pro-inflammatory cytokine production (TNF-α, IL-6) and impaired bacterial clearance, suggesting that PER2 modulates the host immune response to mycobacterial infection.

### 5.3 Parasitic Infections

**Plasmodium falciparum**: Malaria parasites exhibit circadian rhythms in their intraerythrocytic developmental cycle, and host PER2 expression influences parasite synchronization. PER2-deficient mice show altered parasite rhythms and reduced parasitemia, suggesting that the host clock influences parasite fitness.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 PER2 as a Drug Target

The development of pharmacological agents targeting PER2 is an emerging field, driven by the recognition that circadian disruption contributes to numerous diseases. Current approaches include:

**Small-molecule stabilizers**: Compounds that inhibit CK1ε/δ activity stabilize PER2 and lengthen the circadian period. The most advanced of these is **PF-670462**, a selective CK1ε/δ inhibitor that has shown efficacy in preclinical models of FASPS and bipolar disorder. PF-670462 binds to the ATP-binding pocket of CK1ε/δ with an IC50 of approximately 7 nM for CK1ε and 14 nM for CK1δ. Chronic administration of PF-670462 in mice lengthens the circadian period by 1.5-2 hours and normalizes sleep-wake cycles in a mouse model of FASPS carrying the S662G mutation.

**CRY-binding modulators**: Compounds that enhance the PER2-CRY interaction stabilize the repressive complex and lengthen the period. **KL001** is a carbazole derivative that binds to CRY1/2 and prevents their ubiquitination, thereby stabilizing the PER-CRY complex. KL001 has been shown to lengthen the circadian period in human cells and to inhibit the growth of cancer cells with high PER2 expression.

**HDAC inhibitors**: Since PER2 recruits HDAC1/2 to repress transcription, HDAC inhibitors (e.g., vorinostat, romidepsin) can modulate PER2 target gene expression. However, these agents are non-specific and their effects on circadian rhythms are complex.

### 6.2 FDA-Approved Drugs with PER2-Modulating Activity

Several FDA-approved drugs have been shown to modulate PER2 expression or activity:

| **Drug** | **Class** | **Effect on PER2** | **Clinical Indication** |
|---|---|---|---|
| Lithium | Mood stabilizer | Lengthens circadian period; increases PER2 expression | Bipolar disorder |
| Valproic acid | Anticonvulsant | Increases PER2 expression via HDAC inhibition | Bipolar disorder, epilepsy |
| Dexamethasone | Glucocorticoid | Phase-shifts PER2 expression in peripheral tissues | Anti-inflammatory |
| Melatonin | Hormone | Modulates PER2 expression in the SCN | Circadian rhythm disorders |
| Metformin | Biguanide | Activates AMPK, which phosphorylates PER2 at S71 | Type 2 diabetes |
| Rapamycin | mTOR inhibitor | Increases PER2 stability via reduced translation | Immunosuppression, cancer |

### 6.3 Gene Therapy Approaches

**CRISPR-Cas9 correction of FASPS mutations**: Preclinical studies have demonstrated the feasibility of correcting the S662G mutation in patient-derived induced pluripotent stem cells (iPSCs) using CRISPR-Cas9 homology-directed repair. Corrected iPSCs differentiated into SCN neurons exhibit normal circadian periods, providing proof-of-concept for gene therapy in FASPS.

**AAV-mediated PER2 overexpression**: Adeno-associated virus (AAV) vectors encoding PER2 have been developed for the treatment of circadian disruption in neurodegenerative diseases. Intracerebroventricular injection of AAV9-PER2 in a mouse model of Alzheimer's disease restores circadian rhythms and improves cognitive function.

### 6.4 Pharmacogenomic Considerations

The *PER2* genotype influences the response to several drugs:

- **Lithium**: The rs934945 (V659M) variant is associated with reduced lithium response in bipolar disorder patients. This is consistent with the observation that V659M reduces CK1ε binding, and lithium's chronobiological effects are mediated in part through CK1ε inhibition.

- **Cisplatin**: PER2 expression levels predict cisplatin sensitivity in ovarian cancer cells. Tumors with high PER2 expression are more sensitive to cisplatin due to enhanced p53-mediated apoptosis. The S662G mutation, which stabilizes PER2, is associated with increased cisplatin sensitivity.

- **Methotrexate**: The timing of methotrexate administration relative to the circadian cycle affects its efficacy and toxicity. PER2 expression levels in peripheral blood mononuclear cells can be used to optimize chronomodulated chemotherapy regimens.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides comprehensive database accessions for the *PER2* gene and its protein product:

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| HGNC | 8846 | Gene symbol and nomenclature |
| NCBI Gene | 8864 | Gene records, genomic context, and expression data |
| Ensembl | ENSG00000132326 | Gene annotation, transcripts, and variation |
| UniProt | O15055 | Protein sequence, PTMs, and domain annotations |
| RCSB PDB | (No full-length structure) | Domain structures via homology models |
| AlphaFold DB | O15055 | Predicted full-length structure |
| ClinVar | Gene: 8864 | Pathogenic variants and clinical classifications |
| OMIM | 603426 | Gene description and associated phenotypes |
| RefSeq (mRNA) | NM_022817.3 | Canonical transcript sequence |
| RefSeq (Protein) | NP_073728.3 | Canonical protein sequence |
| STRING | 9606.ENSP00000254657 | Protein-protein interaction network |
| BioGRID | 112590 | Physical and genetic interactions |
| PhosphoSitePlus | O15055 | Post-translational modification sites |
| GTEx | ENSG00000132326 | Tissue-specific expression and eQTLs |
| TCGA | PER2 | Cancer genomics and expression data |
| GWAS Catalog | PER2 | Genome-wide association study variants |
| Reactome | R-HSA-1368108 | Circadian clock pathway annotations |
| KEGG | hsa04710 | Circadian rhythm pathway |
| Gene Ontology (GO) | GO:0000978, GO:0005515, GO:0005634 | Molecular function, binding, and localization |

### Gene Ontology Annotations

| **GO Term** | **Accession** | **Category** | **Description** |
|---|---|---|---|
| Transcription repressor activity | GO:0001227 | Molecular Function | Repression of RNA polymerase II transcription |
| Protein binding | GO:0005515 | Molecular Function | Non-covalent protein-protein interactions |
| PAS domain binding | GO:0071535 | Molecular Function | Binding to PAS domain-containing proteins |
| Nucleus | GO:0005634 | Cellular Component | Localization in the nucleus |
| Cytoplasm | GO:0005737 | Cellular Component | Localization in the cytoplasm |
| Circadian rhythm | GO:0007623 | Biological Process | Regulation of the ~24-hour biological cycle |
| DNA damage response | GO:0006974 | Biological Process | Cellular response to DNA damage |
| Negative regulation of transcription | GO:0000122 | Biological Process | Inhibition of transcriptional activity |

---

## Related Clinical & Scientific Guides

* [IRF6 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/irf6-gene-structure-function-pathway)
* [G6PD (Glucose-6-Phosphate Dehydrogenase): NADPH Production, Favism, and Malaria Protection Variants](/knowledge/bioinformatics/genes/medical-genetics/g6pd-gene-structure-function-pathway)
* [WNT7A Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/medical-genetics/wnt7a-gene-structure-function-pathway)


## References

1. Toh KL, Jones CR, He Y, et al. An hPer2 phosphorylation site mutation in familial advanced sleep phase syndrome. *Science*. 2001;291(5506):1040-1043. doi:10.1126/science.1057499

2. Zheng B, Larkin DW, Albrecht U, et al. The mPer2 gene encodes a functional component of the mammalian circadian clock. *Nature*. 1999;400(6740):169-173. doi:10.1038/22118

3. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. *Cell*. 2002;111(1):41-50. doi:10.1016/S0092-8674(02)00961-3

4. Kiyohara YB, Tagao S, Tamanini F, et al. The BMAL1 C terminus regulates the circadian transcription feedback loop. *Proc Natl Acad Sci USA*. 2006;103(26):10074-10079. doi:10.1073/pnas.0601416103

5. Meng QJ, Maywood ES, Bechtold DA, et al. Entrainment of disrupted circadian behavior through inhibition of casein kinase 1 (CK1) enzymes. *Proc Natl Acad Sci USA*. 2010;107(34):15240-15245. doi:10.1073/pnas.1005101107

6. Lamia KA, Sachdeva UM, DiTacchio L, et al. AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. *Science*. 2009;326(5951):437-440. doi:10.1126/science.1172156

7. Asher G, Gatfield D, Stratmann M, et al. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. *Cell*. 2008;134(2):317-328. doi:10.1016/j.cell.2008.06.050

8. Guillaumond F, Dardente H, Giguère V, Cermakian N. Differential control of Bmal1 circadian transcription by REV-ERB and ROR nuclear receptors. *J Biol Rhythms*. 2005;20(5):391-403. doi:10.1177/0748730405277232

9. Sun Y, Yang Z, Niu Z, et al. The circadian gene Per2 is a novel tumor suppressor that modulates the DNA damage response. *Cancer Res*. 2010;70(8):3345-3354. doi:10.1158/0008-5472.CAN-09-4190

10. Yang X, Wood PA, Oh EY, Du-Quiton J, Ansell CM, Hrushesky WJ. Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its